Author Ziepert, Marita

• 2007 | Journal Article | 
  ​ ​Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens​
  Trümper, L.; Zwick, C.; Ziepert, M.; Hohloch, K.; Schmits, R.; Mohren, M. & Liersch, R. et al.​ (2007) 
  Annals of Oncology, 19(3) pp. 538​-544​.​ DOI: https://doi.org/10.1093/annonc/mdm497 
  ​Details  DOI 

• 2008 | Conference Abstract
  ​ ​Expression of intracellular ABC transporter A3 in aggressive non-Hodgkin lymphoma​
  Chapuy, B. ; Corsham, S.; Klapper, W.; Ziepert, M.; Truemper, L. H. & Wulf, G.​ (2008)
  Annals of Oncology, 19 pp. 199​-200. ​10th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
  Oxford​: Oxford Univ Press.
  ​Details  WoS 

• 2008 | Conference Abstract
  ​ ​Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with Diffuse Large B-cell Lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL)​
  Schubert, J.; Ziepert, M.; Lengfelder, E.; Mohren, M.; Peter, N.; Reiser, M. & Clemens, M. et al.​ (2008)
  Onkologie, 31 
  Basel​: Karger.
  ​Details  WoS 

• 2008 | Conference Abstract
  ​ ​T-cell lymphomas in studies of the German high-grade NHL study group (DSHNHL)​
  Schmitz, N.; Ziepert, M.; Nickelsen, M.; Truemper, L. H.; Glass, B.; Loeffler, M. & Ho, A. D. et al.​ (2008)
  Annals of Oncology, 19 ​10th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
  Oxford​: Oxford Univ Press.
  ​Details  WoS 

• 2008 | Journal Article
  ​ ​Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma​
  Ziepert, M.; Schmits, R.; Truemper, L. H.; Pfreundschuh, M. & Loeffler, M.​ (2008) 
  Annals of Oncology, 19(4) pp. 752​-762​.​ DOI: https://doi.org/10.1093/annonc/mdm541 
  ​Details  DOI  PMID  PMC  WoS 

• 2008 | Journal Article
  ​ ​Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)​
  Pfreundschuh, M.; Schubert, J.; Ziepert, M.; Schmits, R.; Mohren, M.; Lengfelder, E. & Reiser, M. et al.​ (2008) 
  The Lancet Oncology, 9(2) pp. 105​-116​.​ DOI: https://doi.org/10.1016/S1470-2045(08)70002-0 
  ​Details  DOI  PMID  PMC  WoS 

• 2009 | Conference Abstract
  ​ ​Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL)​
  Schmitz, N.; Ziepert, M.; Nickelsen, M.; Wolf, S. P.; Truemper, L. H.; Loeffler, M. & Ho, A. D. et al.​ (2009)
  Journal of Clinical Oncology, 27(15) ​45th Annual Meeting of the American-Society-of-Clinical-Oncology​, Orlando, FL.
  Alexandria​: Amer Soc Clinical Oncology.
  ​Details  PMID  PMC  WoS 

• 2009 | Conference Abstract
  ​ ​Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High - Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)​
  Schmitz, N.; Nickelsen, M.; Ziepert, M.; Haenel, M.; Borchmann, P.; Viardot, A. & Nickenig, C. et al.​ (2009)
  Blood, 114(22) ​51st Annual Meeting of the American-Society-of-Hematology​, New Orleans, LA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2009 | Conference Abstract
  ​ ​Outcome of Elderly Patients with DLBCL Failing R-CHOP: The Role of Rituximab and High Dose Therapy in Second Line Treatment. A Retrospective Analysis From the RICOVER 60 Trial.​
  Glass, B.; Borgerding, A.; Ziepert, M.; Nickelsen, M.; Loeffler, M.; Pfreundschuh, M. & Truemper, L. H. et al.​ (2009)
  Blood, 114(22) pp. 1430​-1431. ​51st Annual Meeting of the American-Society-of-Hematology​, New Orleans, LA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2009 | Journal Article | 
  ​ ​Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials​
  Bernd, H.-W.; Ziepert, M.; Thorns, C.; Klapper, W.; Wacker, H.-H.; Hummel, M. & Stein, H. et al.​ (2009) 
  HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(11) pp. 1569​-1580​.​ DOI: https://doi.org/10.3324/haematol.2009.008862 
  ​Details  DOI  PMID  PMC  WoS 

• 2009 | Journal Article | 
  ​ ​Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial​
  Schoof, N.; von Bonin, F.; Zeynalova, S.; Ziepert, M.; Jung, W.; Loeffler, M. & Pfreundschuh, M. et al.​ (2009) 
  Annals of Oncology, 20(9) pp. 1548​-1554​.​ DOI: https://doi.org/10.1093/annonc/mdp110 
  ​Details  DOI  PMID  PMC  WoS 

• 2010 | Journal Article
  ​ ​Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group​
  Schmitz, N.; Truemper, L. H.; Ziepert, M.; Nickelsen, M.; Ho, A. D.; Metzner, B. & Peter, N. et al.​ (2010) 
  Blood, 116(18) pp. 3418​-3425​.​ DOI: https://doi.org/10.1182/blood-2010-02-270785 
  ​Details  DOI  PMID  PMC  WoS 

• 2010 | Journal Article
  ​ ​High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma​
  Glass, B.; Ziepert, M.; Reiser, M.; Freund, M.; Trümper, L. ; Metzner, B. & Feller, A. et al.​ (2010) 
  Annals of Oncology, 21(11) pp. 2255​-2261​.​ DOI: https://doi.org/10.1093/annonc/mdq235 
  ​Details  DOI  PMID  PMC  WoS 

• 2010 | Journal Article
  ​ ​Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL​
  Ott, G.; Ziepert, M.; Klapper, W.; Horn, H.; Szczepanowski, M.; Bernd, H.-W. & Thorns, C. et al.​ (2010) 
  Blood, 116(23) pp. 4916​-4925​.​ DOI: https://doi.org/10.1182/blood-2010-03-276766 
  ​Details  DOI  PMID  PMC  WoS 

• 2010 | Journal Article
  ​ ​A Functional Polymorphism in the NAD(P)H Oxidase Subunit CYBA Is Related to Gene Expression, Enzyme Activity, and Outcome in Non-Hodgkin Lymphoma​
  Hoffmann, M.; Schirmer, M. A.; Tzvetkov, M. V.; Kreuz, M.; Ziepert, M.; Wojnowski, L. & Kube, D. et al.​ (2010) 
  Cancer Research, 70(6) pp. 2328​-2338​.​ DOI: https://doi.org/10.1158/0008-5472.CAN-09-2388 
  ​Details  DOI  PMID  PMC  WoS 

• 2011 | Conference Abstract
  ​ ​7-year follow-up of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)​
  Zwick, C.; Ziepert, M.; Zeynalova, S.; Lengfelder, E.; Steinhauer, H.; Clemens, M. & Nickenig, C. et al.​ (2011)
  Onkologie, 34 
  Basel​: Karger.
  ​Details  WoS 

• 2011 | Conference Abstract
  ​ ​First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant​
  d'Amore, F.; da Silva, M. G.; Leppa, S.; Relander, T.; Pezzutto, A.; Lauritzsen, G. F. & Weidmann, E. et al.​ (2011)
  Blood, 118(21) ​53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)​, San Diego, CA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2011 | Conference Abstract
  ​ ​EXCELLENT OUTCOME IN AGGRESSIVE NON HODGKIN'S LYMPHOMA IN ADOLESCENTS AND YOUNG ADULTS TREATED WITH CHOP-BASED REGIMENS IN DSHNHL TRIALS: AGE IS NOT A RISK FACTOR IN PATIENTS BELOW 50 YEARS​
  Truemper, L. H.; Zeynalova, S.; Ziepert, M.; Glass, B.; Loeffler, M.; Schmitz, N. & Pfreundschuh, M.​ (2011)
  Annals of Oncology, 22 ​11th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
  Oxford​: Oxford Univ Press.
  ​Details  WoS 

• 2011 | Conference Abstract
  ​ ​CONVENTIONAL CHEMOIMMUNOTHERAPY (R-CHOEP-14) OR HIGH-DOSE THERAPY (R-MEGA-CHOEP) FOR YOUNG, HIGH-RISK PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: FINAL RESULTS OF THE RANDOMIZED MEGA-CHOEP-TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)​
  Schmitz, N.; Nickelsen, M.; Ziepert, M.; Borchmann, P.; Nickenig, C.; Viardot, A. & Bentz, M. et al.​ (2011)
  Annals of Oncology, 22 pp. 106​-107. ​11th International Conference on Malignant Lymphoma​, Lugano, SWITZERLAND.
  Oxford​: Oxford Univ Press.
  ​Details  WoS 

• 2012 | Conference Abstract
  ​ ​First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy​
  d'Amore, F.; Leppa, S.; da Silva, M. C.; Relander, T.; Brown, P. D. N.; Weidmann, E. & Lauritzsen, G. F. et al.​ (2012)
  Blood, 120(21) ​54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)​, Atlanta, GA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2012 | Journal Article
  ​ ​Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)​
  Schmitz, N.; Nickelsen, M.; Ziepert, M.; Haenel, M.; Borchmann, P.; Schmidt, C. D. & Viardot, A. et al.​ (2012) 
  The Lancet Oncology, 13(12) pp. 1250​-1259​.​ DOI: https://doi.org/10.1016/S1470-2045(12)70481-3 
  ​Details  DOI  PMID  PMC  WoS 

• 2012 | Journal Article
  ​ ​Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non-Hodgkin Lymphoma​
  Heemann, C.; Kreuz, M.; Stoller, I.; Schoof, N.; von Bonin, F.; Ziepert, M. & Loeffler, M. et al.​ (2012) 
  Clinical Cancer Research, 18(13) pp. 3637​-3647​.​ DOI: https://doi.org/10.1158/1078-0432.CCR-11-3299 
  ​Details  DOI  PMID  PMC  WoS 

• 2013 | Journal Article
  ​ ​CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial​
  Binder, C.; Ziepert, M.; Pfreundschuh, M.; Duehrsen, U.; Eimermacher, H.; Aldaoud, A. & Rosenwald, A. et al.​ (2013) 
  Annals of Hematology, 92(11) pp. 1521​-1528​.​ DOI: https://doi.org/10.1007/s00277-013-1880-4 
  ​Details  DOI  PMID  PMC  WoS 

• 2013 | Journal Article
  ​ ​MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma​
  Horn, H.; Ziepert, M.; Becher, C.; Barth, T. F. E.; Bernd, H.-W.; Feller, A. C. & Klapper, W. et al.​ (2013) 
  Blood, 121(12) pp. 2253​-2263​.​ DOI: https://doi.org/10.1182/blood-2012-06-435842 
  ​Details  DOI  PMID  PMC  WoS 

• 2014 | Journal Article | Research Paper
  ​ ​Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma​
  Koch, R.; Demant, M.; Aung, T.; Diering, N.; Cicholas, A.; Chapuy, B.   & Wenzel, D. et al.​ (2014) 
  Blood, 123(14) pp. 2189​-2198​.​ DOI: https://doi.org/10.1182/blood-2013-08-523886 
  ​Details  DOI  PMID  PMC  WoS 

• 2014 | Journal Article | Letter Note
  ​ ​Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens​
  Hohloch, K.; Zeynalova, S.; Held, G.; Ziepert, M.; Loeffler, M.; Wulf, G. & Schmitz, N. et al.​ (2014) 
  Leukemia, 28(11) pp. 2260​-2263​.​ DOI: https://doi.org/10.1038/leu.2014.213 
  ​Details  DOI  PMID  PMC  WoS 

• 2014 | Journal Article | 
  ​ ​Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL​
  Hohloch, K.; Zwick, C.; Ziepert, M.; Hasenclever, D.; Kaiser, U.; Engert, A. & Hoeffkes, H.-G. et al.​ (2014) 
  SpringerPlus, 3 art. 5​.​ DOI: https://doi.org/10.1186/2193-1801-3-5 
  ​Details  DOI  PMID  PMC  WoS 

• 2015 | Conference Abstract
  ​ ​Liposomal formulation of vincristine allows for doubling the dose compared to conventional vincristine: Results of the first futility analysis of the OPTIMAL > 60 study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)​
  Duecker, S.; Poeschel, V.; Wolf, A.; Held, G.; Murawski, N.; Zwick, C. & Haenel, M. et al.​ (2015)
  Oncology Research and Treatment, 38 pp. 197​-198. 
  Basel​: Karger.
  ​Details  WoS 

• 2015 | Conference Abstract
  ​ ​Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R-CHOP​
  Hohloch, K.; Altmann, B.; Pfreundschuh, M.; Loeffler, M.; Schmitz, N.; Ziepert, M. & Truemper, L. H.​ (2015)
  Blood, 126(23) ​57th Annual Meeting of the American-Society-of-Hematology​, Orlando, FL.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2015 | Conference Abstract
  ​ ​Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma​
  Chapuy, B. ; Dunford, A. J.; Stewart, C.; Kamburov, A.; Kim, J.; Roemer, M. G. M. & Ziepert, M. et al.​ (2015)
  Blood, 126(23) ​57th Annual Meeting of the American-Society-of-Hematology​, Orlando, FL.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2015 | Journal Article | Research Paper
  ​ ​Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma​
  Reichwagen, A.; Ziepert, M.; Kreuz, M.; Gödtel-Armbrust, U.; Rixecker, T.; Poeschel, V. & Toliat, M. R. et al.​ (2015) 
  Pharmacogenomics, 16(4) pp. 361​-372​.​ DOI: https://doi.org/10.2217/PGS.14.179 
  ​Details  DOI  PMID  PMC  WoS 

• 2015 | Journal Article
  ​ ​Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma​
  Horn, H.; Ziepert, M.; Wartenberg, M.; Staiger, A. M.; Barth, T. F. E.; Bernd, H.-W. & Feller, A. C. et al.​ (2015) 
  Leukemia, 29(7) pp. 1564​-1570​.​ DOI: https://doi.org/10.1038/leu.2015.43 
  ​Details  DOI  PMID  PMC  WoS 

• 2016 | Journal Article
  ​ ​Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL.​
  Zettl, F.; Ziepert, M.; Altmann, B.; Zeynalova, S.; Loeffler, M.; Schmitz, N. & Pfreundschuh, M. et al.​ (2016) 
  Journal of Clinical Oncology, 34(15_suppl) pp. 7539​-7539​.​ DOI: https://doi.org/10.1200/JCO.2016.34.15_suppl.7539 
  ​Details  DOI 

• 2016 | Journal Article | Research Paper
  ​ ​Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma​
  Hohloch, K.; Zeynalova, S.; Chapuy, B. ; Pfreundschuh, M.; Loeffler, M.; Ziepert, M. & Feller, A. C. et al.​ (2016) 
  Annals of Hematology, 95(7) pp. 1121​-1128​.​ DOI: https://doi.org/10.1007/s00277-016-2671-5 
  ​Details  DOI  PMID  PMC  WoS 

• 2016 | Journal Article
  ​ ​Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL​
  Koch, K.; Hoster, E.; Ziepert, M.; Unterhalt, M.; Ott, G.; Rosenwald, A. & Hansmann, M. L. et al.​ (2016) 
  Annals of Oncology, 27(7) pp. 1323​-1329​.​ DOI: https://doi.org/10.1093/annonc/mdw185 
  ​Details  DOI  PMID  PMC  WoS 

• 2017 | Journal Article
  ​ ​Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group​
  Staiger, A. M.; Ziepert, M.; Horn, H.; Scott, D. W.; Barth, T. F.; Bernd, H.-W. & Feller, A. C. et al.​ (2017) 
  Journal of Clinical Oncology, 35(22) pp. 2515​-2526​.​ DOI: https://doi.org/10.1200/JCO.2016.70.3660 
  ​Details  DOI 

• 2017 | Journal Article
  ​ ​Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.​
  Murawski, N.; Amam, J.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al.​ (2017) 
  Journal of Clinical Oncology, 35(15_suppl) pp. 7539​-7539​.​ DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7539 
  ​Details  DOI 

• 2017 | Journal Article
  ​ ​Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.​
  Pfreundschuh, M.; Christofyllakis, K.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A. & Neubauer, A. et al.​ (2017) 
  Journal of Clinical Oncology, 35(15_suppl) pp. 7506​-7506​.​ DOI: https://doi.org/10.1200/JCO.2017.35.15_suppl.7506 
  ​Details  DOI 

• 2017 | Journal Article
  ​ ​Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients​
  Pfreundschuh, M.; Murawski, N.; Zeynalova, S.; Ziepert, M.; Loeffler, M.; Hänel, M. & Dierlamm, J. et al.​ (2017) 
  British Journal of Haematology, 179(3) pp. 410​-420​.​ DOI: https://doi.org/10.1111/bjh.14860 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant​
  d'Amore, F.; Leppä, S.; Silva, M. G. da; Relander, T.; Lauritzsen, G. F.; Brown, P. D. N. & Pezzutto, A. et al.​ (2018) 
  Blood, 132(Supplement 1) pp. 998​-998​.​ DOI: https://doi.org/10.1182/blood-2018-99-110429 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group​
  Staiger, A. M.; Altenbuchinger, M.; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Huettl, K. et al.​ (2018) 
  Blood, 132(Supplement 1) pp. 343​-343​.​ DOI: https://doi.org/10.1182/blood-2018-99-112450 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.​
  Pfreundschuh, M.; Murawski, N.; Ziepert, M.; Altmann, B.; Dreyling, M. H.; Borchmann, P. & Luminari, S. et al.​ (2018) 
  Journal of Clinical Oncology, 36(15_suppl) pp. 7574​-7574​.​ DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.7574 
  ​Details  DOI 

• 2018 | Journal Article
  ​ ​Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA​
  Poeschel, V.; Held, G.; Ziepert, M.; Altmann, B.; Witzens-Harig, M.; Holte, H. & Thurner, L. et al.​ (2018) 
  Blood, 132(Supplement 1) pp. 781​-781​.​ DOI: https://doi.org/10.1182/blood-2018-99-112403 
  ​Details  DOI 

• 2018 | Journal Article | Research Paper
  ​ ​Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes​
  Chapuy, B. ; Stewart, C.; Dunford, A. J.; Kim, J.; Kamburov, A.; Redd, R. A. & Lawrence, M. S. et al.​ (2018) 
  Nature Medicine, 24(5) pp. 679​-690​.​ DOI: https://doi.org/10.1038/s41591-018-0016-8 
  ​Details  DOI 

• 2018 | Journal Article | Erratum
  ​ ​Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes​
  Chapuy, B.; Stewart, C.; Dunford, A. J.; Kim, J.; Kamburov, A.; Redd, R. A. & Lawrence, M. S. et al.​ (2018) 
  Nature Medicine, 24(8) pp. 1290​-1291​.​ DOI: https://doi.org/10.1038/s41591-018-0097-4 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial​
  Poeschel, V.; Held, G.; Ziepert, M.; Witzens-Harig, M.; Holte, H.; Thurner, L. & Borchmann, P. et al.​ (2019) 
  The Lancet, 394(10216) pp. 2271​-2281​.​ DOI: https://doi.org/10.1016/S0140-6736(19)33008-9 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL​
  Staiger, A. M.; Altenbuchinger, M. ; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Hüttl, K. S. et al.​ (2019) 
  Leukemia, 34(2) pp. 543​-552​.​ DOI: https://doi.org/10.1038/s41375-019-0573-y 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study​
  Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Hänel, M. & Truemper, L. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 1589​-1589​.​ DOI: https://doi.org/10.1182/blood-2019-123637 
  ​Details  DOI 

• 2019 | Journal Article
  ​ ​Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)​
  Zettl, F.; Braulke, F.; Ziepert, M.; Viardot, A.; Kahl, C.; Prange-Krex, G. & Korfel, A. et al.​ (2019) 
  Blood, 134(Supplement_1) pp. 4073​-4073​.​ DOI: https://doi.org/10.1182/blood-2019-122948 
  ​Details  DOI 

• 2019 | Journal Article | 
  ​ ​The impact of SOCS1 mutations in diffuse large B‐cell lymphoma​
  Mellert, K.; Martin, M.; Lennerz, J. K.; Lüdeke, M.; Staiger, A. M.; Kreuz, M. & Löffler, M. et al.​ (2019) 
  British Journal of Haematology, 187(5) pp. 627​-637​.​ DOI: https://doi.org/10.1111/bjh.16147 
  ​Details  DOI  PMID  PMC 

Researcher

Sort

Items per Page